- Home
- CHI vs XERS Comparison
CHI vs XERS Comparison
Compare CHI & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHI
- XERS
- Stock Information
- Founded
- CHI 2002
- XERS 2005
- Country
- CHI United States
- XERS United States
- Employees
- CHI N/A
- XERS N/A
- Industry
- CHI Investment Managers
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- CHI Finance
- XERS Health Care
- Exchange
- CHI Nasdaq
- XERS Nasdaq
- Market Cap
- CHI 820.8M
- XERS 752.7M
- IPO Year
- CHI N/A
- XERS 2018
- Fundamental
- Price
- CHI $10.44
- XERS $5.02
- Analyst Decision
- CHI
- XERS Strong Buy
- Analyst Count
- CHI 0
- XERS 6
- Target Price
- CHI N/A
- XERS $6.25
- AVG Volume (30 Days)
- CHI 186.2K
- XERS 2.0M
- Earning Date
- CHI 01-01-0001
- XERS 08-07-2025
- Dividend Yield
- CHI 9.90%
- XERS N/A
- EPS Growth
- CHI N/A
- XERS N/A
- EPS
- CHI N/A
- XERS N/A
- Revenue
- CHI N/A
- XERS $222,551,000.00
- Revenue This Year
- CHI N/A
- XERS $35.31
- Revenue Next Year
- CHI N/A
- XERS $19.65
- P/E Ratio
- CHI N/A
- XERS N/A
- Revenue Growth
- CHI N/A
- XERS 29.88
- 52 Week Low
- CHI $9.70
- XERS $2.10
- 52 Week High
- CHI $11.61
- XERS $6.07
- Technical
- Relative Strength Index (RSI)
- CHI 52.98
- XERS 51.52
- Support Level
- CHI $10.30
- XERS $4.99
- Resistance Level
- CHI $10.61
- XERS $5.22
- Average True Range (ATR)
- CHI 0.10
- XERS 0.23
- MACD
- CHI -0.01
- XERS -0.02
- Stochastic Oscillator
- CHI 45.16
- XERS 43.37
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).